01 2MabThera
02 14MabThera/Rituxan
03 4Mabthera/Rituxan
04 2Rituxan/Gazyva Revenues
05 5Rituximab BS (KHK)
06 1Rituximab BS (Khk)
07 4Ruxience
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 5,037
2018 Revenue in Millions : 5,347
Growth (%) : -6
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 1,635
2018 Revenue in Millions : 1,608
Growth (%) : 2
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,132
2019 Revenue in Millions : 1,603
Growth (%) : -29
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 1,133
2019 Revenue in Millions : 1,768
Growth (%) : -36
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 112
2019 Revenue in Millions : 92
Growth (%) : 22
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 3,572
2019 Revenue in Millions : 5,448
Growth (%) : -34
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 170
2019 Revenue in Millions : -1
Growth (%) :
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 609
2020 Revenue in Millions : 1,078
Growth (%) : -44
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 2,151
2020 Revenue in Millions : 3,398
Growth (%) : -38
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 491
2020 Revenue in Millions : 170
Growth (%) : 189
LOOKING FOR A SUPPLIER?
